Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Amylin Pharmaceuticals, Inc. |
---|---|
Information provided by: | Amylin Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00042601 |
This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 |
Drug: Pramlintide acetate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Efficacy Study |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
For Healthy Volunteers:
For Subjects with Type 1 or Type 2 Diabetes:
Study ID Numbers: | 137-149 |
Study First Received: | August 1, 2002 |
Last Updated: | November 5, 2007 |
ClinicalTrials.gov Identifier: | NCT00042601 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Hypoglycemic Agents Autoimmune Diseases Metabolic Diseases Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus |
Endocrine System Diseases Pramlintide Diabetes Mellitus Type 1 Endocrinopathy Glucose Metabolism Disorders Metabolic Disorder |
Hypoglycemic Agents Autoimmune Diseases Metabolic Diseases Immune System Diseases Diabetes Mellitus, Type 1 Physiological Effects of Drugs |
Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Pramlintide Glucose Metabolism Disorders Pharmacologic Actions |